4//SEC Filing
Moseley Ken 4
Accession 0001358403-17-000139
CIK 0001358403other
Filed
Jul 16, 8:00 PM ET
Accepted
Jul 17, 4:20 PM ET
Size
9.8 KB
Accession
0001358403-17-000139
Insider Transaction Report
Form 4
Moseley Ken
Vice President
Transactions
- Sale
Common Stock
2017-07-13$12.26/sh−13,823$169,470→ 491 total - Exercise/Conversion
Common Stock
2017-07-13$2.55/sh+13,823$35,249→ 14,314 total - Exercise/Conversion
Stock Option (right to buy)
2017-07-13−13,823→ 0 totalExercise: $2.55Exp: 2022-12-31→ Common Stock (13,823 underlying)
Holdings
- 635(indirect: By Spouse)
Common Stock
Footnotes (4)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 3, 2017 by the Reporting Person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.25 to $12.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]Includes 147 shares acquired by the Reporting Person under the Issuer's 2014 Employee Purchase Plan on December 9, 2016.
- [F4]25% of the shares subject to the stock option vested and became exercisable on January 1, 2014, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
Documents
Issuer
BELLICUM PHARMACEUTICALS, INC
CIK 0001358403
Entity typeother
Related Parties
1- filerCIK 0001626895
Filing Metadata
- Form type
- 4
- Filed
- Jul 16, 8:00 PM ET
- Accepted
- Jul 17, 4:20 PM ET
- Size
- 9.8 KB